Classification of gastrointestinal stromal tumor syndromes.
Gopie P, Mei L, Faber AC, Grossman SR, Smith SC, Boikos SA · Endocrine-related cancer
Sarcoma subtypes
Abstract
KIT PDGFRA KIT/PDGFRA SDHA B C D BRAF NF1 KIT PDGFRA SDH NF1 Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, thought to derive from neoplastic outgrowth of the interstitial cells of Cajal. Building on recent advances in recognition, classification and diagnosis, the past two decades have seen a changing paradigm with molecular diagnostics and targeted therapies.andmutations account for 85-90% of GIST carcinogenesis. However, the remaining 10-15% of GISTs, which until recently were calledwild-type GISTs, have been found to have one of the several mutations, including in the,,,,andgenes. Though most of such GISTs are sporadic, a number of families with high incidence rates of GISTs and other associated clinical manifestations have been reported and found to harbor germline mutations in,,subunits andThe goal of this review is to describe the mutations, clinical manifestations and therapeutic implications of syndromic and inherited GISTs in light of recent studies of their clinicopathologic range and pathogenesis.
Shown exactly as published on PubMed. Your oncologist is the right person to judge whether these findings apply to your situation.
Publication type
Source: PubMed, PMID 29170162. Always confirm details with the original publication or your oncologist.